UPA-ECx1 is developed by Oregon Health and Science University.

What development phase is UPA-ECx1 in?

UPA-ECx1 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

UPA-ECx1

Oregon Health and Science University · FDA-approved active Small molecule Quality 0/100

UPA-ECx1, developed by Oregon Health and Science University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current market availability. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	UPA-ECx1
Also known as	Ella, Ella-One
Sponsor	Oregon Health and Science University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results